Understanding The Science of Zantac Breast Cancer

Court cases in the months to come could focus on the scientific evidence that Zantac (ranitidine) increases the risks of breast cancer

Saturday, August 15, 2020 - As written earlier, being diagnosed with breast cancer is many woman's greatest fear. Women are worried that they may have inadvertently sown the seeds of developing breast cancer by using anti-heartburn and acid reflux medicine Zantac (ranitidine), regularly and for years. Zantac has been promoted as the world's best-selling brand of heartburn medicine, treating around 15 million Americans per year and earning billions of dollars in profit for the Sanofi, the company that makes and sells it. Sanofi is under investigation by the US Department of Justice for allegedly lying about what they knew was Zantac's potential to cause cancer. Many women that have developed breast cancer have hired a Zantac Breast Cancer Lawyer and filed a lawsuit against Sanofi seeking reimbursement of their medical expenses, lost wages, pain, and suffering, and other damages they may have had to endure as a result of Sanofi's negligence. Sanofi may be intending to defend themselves in court by claiming that the testing lab that found the elevated levels of carcinogenic NDMA in Zantac, themselves caused the increase by super-heating samples they tested. Scientific evidence from both sides of the courtroom will become available in the months to come and it should be interesting to see which side is right.

In the meantime, we can look at what has been published linking Zantac and breast cancer in recent years. A 2008, peer-reviewed study by the American Association for Cancer Research examined the relationship and concluded: "Use of H2 blockers, in general, is not associated with an increased risk of breast cancer, although current use of ranitidine may increase risk of hormone-receptor-positive ductal carcinoma." The paper describes Zantac (ranitidine) as being one of the heavily-prescribed medicines that could cause an increase in cancer. "Histamine2-receptor antagonist (H2 blocker) drugs are used to treat gastric and duodenal ulcers, gastroesophageal reflux disease, and high levels of gastric acidity. There are four H2 blocker medications approved for use in the United States: cimetidine, ranitidine, famotidine, and nizatidine." The MayoClinic describes hormone receptor-positive ductal carcinoma as one that may be fueled by the production of a woman's hormones. "Some breast cancers are sensitive to your body's naturally occurring female hormones - estrogen and progesterone. The breast cancer cells have receptors on the outside of their walls that can catch specific hormones that circulate through your body." A paper on the subject of H2 blockers like Zantac and women developing breast cancer confirmed the previous study. "Histamine(2)-receptor antagonist (H(2) blocker) medications are used to treat heartburn, gastroesophageal reflux disease, and ulcers. Some H(2) blockers, specifically cimetidine and ranitidine, also increase serum prolactin concentrations. Given the positive relationship between prolactin levels and postmenopausal breast cancer risk, the use of H(2) blockers is a potential breast cancer risk factor," the NIH wrote.

If you or a loved one has developed breast cancer of other forms of cancer after using Zantac regularly for years you may wish to file a claim. Cases could be consolidated into multidistrict litigation in Federal court once the scientific evidence is analyzed and decided upon by the judge in separate hearings. You may wish to secure your hospital medical records in advance to facilitate filing a Zantac Breast Cancer Lawsuit.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.